The long‐term outcome of patients in the LRF CLL 4 trial: the effect of salvage treatment and biological markers in those surviving 10 years
Author:
Affiliation:
1. Division of Molecular Pathology The Institute of Cancer Research London UK
2. Clinical Trial Service Unit Oxford UK
3. Department of Molecular Pathology Royal Bournemouth Hospital Bournemouth UK
Funder
Leukaemia and Lymphoma Research
Cancer Research UK
Publisher
Wiley
Subject
Hematology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.13824
Reference26 articles.
1. The international prognostic index for patients with CLL (CLL‐IPI) – an international meta‐analysis;Bahlo J.;Journal of Clinical Oncology,2015
2. Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
3. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
4. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
5. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study;BMC Health Services Research;2023-12-05
2. Ibrutinib versus bendamustine plus rituximab for first-line treatment of older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: A lifetime economic research study;2023-02-01
3. The road to chemotherapy-free treatment in chronic lymphocytic leukaemia;Current Opinion in Oncology;2021-09-01
4. Early clinical trials in chronic lymphocytic leukaemia in the UK;British Journal of Haematology;2020-11
5. A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia;Haematologica;2019-10-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3